Table 2.
Activity for drugs used to develop the novel screening approach on Naegleria gruberi.
| Drug | IC50 (μM) | IC90 (μM) | MIC (μM) |
|---|---|---|---|
| Amphotericin B (Abelcet) | 0.48 ± 0.03 | 0.92 ± 0.11 | >1.25, <2.5 |
| Azithromycin (Zithromax) | 0.07 ± 0.01 | 0.27 ± 0.04 | <1.25 |
| Butoconazole nitrate | 0.02 ± 0.00 | 0.03 ± 0.01 | <1.25 |
| Camptothecin | 0.46 ± 0.18 | 11.98 ± 2.60 | >10 |
| Ponatinib (AP24534) | 0.23 ± 0.03 | 0.61 ± 0.14 | <1.25 |
| Pyrimethamine | 0.17 ± 0.03 | 1.64 ± 0.28 | >10 |
| Terbinafine (Lamisil, Terbinex) | 0.96 ± 0.05 | 4.59 ± 0.62 | >5, <10 |
| Thonzonium bromide | 0.13 ± 0.03 | 2.95 ± 0.41 | >10 |
| Tilmicosin | 0.41 ± 0.08 | 2.99 ± 0.54 | >10 |
IC, inhibitory concentration; MIC, minimum inhibitory concentration.